Close Menu

Over at bbgm, Deepak Singh considers a slide that's been circulating which compares the number of approved New Molecular Entities to spending by members of PhRMA from 1970 to the early 2000s. Paul Kedrosky, who presented the slide recently, notes that "the mapping of the genome, and other such inflection points in this failure-prone industry, has done nothing to accelerate [new] drugs, while causing costs to escalate dramatically."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.